<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03077750</url>
  </required_header>
  <id_info>
    <org_study_id>VBP-245-MCV</org_study_id>
    <nct_id>NCT03077750</nct_id>
  </id_info>
  <brief_title>A Study of VBP-245 in Pediatric Patients With Molluscum Contagiosum</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Phase II Study to Evaluate the Efficacy, Tolerability, and Safety of VBP-245 in Pediatric Subjects for the Treatment of Molluscum Contagiosum</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Veloce BioPharma LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Veloce BioPharma LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Phase II Study to Evaluate the&#xD;
      Efficacy, Tolerability, and Safety of Topical VBP-245 in Pediatric Subjects for the Treatment&#xD;
      of Molluscum Contagiosum (VBP-245-MCV).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 27, 2017</start_date>
  <completion_date type="Actual">April 27, 2018</completion_date>
  <primary_completion_date type="Actual">March 30, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in number of MCV lesions</measure>
    <time_frame>60 days</time_frame>
    <description>Number of lesions from baseline to day 60 will be counted and the reduction in number will be recorded.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Molluscum Contagiosum</condition>
  <arm_group>
    <arm_group_label>VBP-245</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VBP-245 Topical Gel Applied to Affected Area BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle Gel Applied to Affected Area BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VBP-245 Topical Gel</intervention_name>
    <description>Topical application BID</description>
    <arm_group_label>VBP-245</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>Vehicle Control With No Active Pharmaceutical Ingredients</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects must meet all of the following inclusion criteria:&#xD;
&#xD;
          1. Males or females aged 2-18 years at screening;&#xD;
&#xD;
          2. MC diagnosed by a general physician, dermatologist or pediatrician who refers it and&#xD;
             treatable by a topical agent;&#xD;
&#xD;
          3. Individuals with at least 1, but not exceeding 15 molluscum selected in designated&#xD;
             treatment area:&#xD;
&#xD;
          4. Individuals whose treatment area is located anywhere on the body except for the&#xD;
             following prohibited areas which include: eye area (including eyelids), lips, mouth&#xD;
             cavity, nasal cavity, inner ear, palms of the hands, soles of the feet or the&#xD;
             anogenital area;&#xD;
&#xD;
          5. Free from any systemic or dermatologic disorder that, in the opinion of the&#xD;
             investigator, will interfere with the study results or increase the risk of adverse&#xD;
             advents;&#xD;
&#xD;
          6. Free from atopic dermatitis in the treatment area that, in the opinion of the&#xD;
             investigator, will potentially get inflamed or irritated during the course of&#xD;
             treatment;&#xD;
&#xD;
          7. Parent or guardian able to give appropriate informed consent as determined by the&#xD;
             approving institutional review board (IRB);&#xD;
&#xD;
          8. Individuals who are generally in good health as determined by the investigator;&#xD;
&#xD;
          9. Willingness and ability of parent or guardian to read, understand, and sign the&#xD;
             IRB-approved informed consent form after the nature of the study has been fully&#xD;
             explained and questions have been answered;&#xD;
&#xD;
         10. Individuals who are willing to not start any new products OTC or prescription&#xD;
             treatments and discontinue any treatment the investigator feels may interfere with the&#xD;
             evaluation of the test products;&#xD;
&#xD;
         11. Individuals who are willing to avoid using cosmetic products, creams, salves, or&#xD;
             ointments to the treatment area(s);&#xD;
&#xD;
         12. Individuals who are willing and able to thoroughly follow the product use&#xD;
             instructions, attend all the scheduled visits and successfully complete the study;&#xD;
&#xD;
         13. Individuals who are willing and able to not begin any office based treatments for the&#xD;
             duration of the study;&#xD;
&#xD;
         14. Female subjects of childbearing age with negative pregnancy test at the enrolment time&#xD;
             in the study;&#xD;
&#xD;
         15. Female subjects who are not breastfeeding at the enrolment time in the study;&#xD;
&#xD;
         16. Female subjects that do not intend to become pregnant during their participation in&#xD;
             the study;&#xD;
&#xD;
         17. Female subjects with reproductive potential must agree to practice medically&#xD;
             acceptable form of birth control during the study â€¢ Medically acceptable forms of&#xD;
             birth control that may be used by the subject and/or his/her partner include: o&#xD;
             Established use of hormonal methods of contraception (oral, injected, implanted, patch&#xD;
             or vaginal ring) Barrier methods of contraception with spermicide: condom or occlusive&#xD;
             cap (diaphragm or cervical/Vault caps) with a spermicidal foam/gel/film/cream or&#xD;
             suppository; o Intrauterine divide (IUD) or intrauterine system (IUS); o Surgical&#xD;
             sterilization (vasectomy, tubal occlusion, bilateral salpingectomy); Abstinence from&#xD;
             heterosexual intercourse; when this is in line with the preferred and usual lifestyle&#xD;
             of the subject. Periodic abstinence (calendar, ovulation, symptothermal, post&#xD;
             ovulation methods) and withdrawal are NOT acceptable methods of contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects meeting the following exclusion criteria will be excluded from the study:&#xD;
&#xD;
          1. Mentally incompetent or unable or not willing to give written informed consent via&#xD;
             parent or guardian or meet study requirements&#xD;
&#xD;
          2. Known history of hypersensitivity to topical povidone-iodine&#xD;
&#xD;
          3. Significant atopic dermatitis surrounding the molluscum contagiosum lesions as judged&#xD;
             by the investigator&#xD;
&#xD;
          4. Individual lesions greater than 5mm in diameter&#xD;
&#xD;
          5. Pregnant, breastfeeding or unwilling to undergo an acceptable form of contraception&#xD;
             for the duration of the study;&#xD;
&#xD;
          6. Molluscum lesions located on the eye area (including eyelids), lips, mouth cavity,&#xD;
             nasal cavity, inner ear, palms of the hands, soles of the feet or the anogenital area;&#xD;
&#xD;
          7. Have participated in an investigational trial within 30 days prior to enrollment;&#xD;
&#xD;
          8. Have required or will require systemic intake of immunosuppressive or immunomodulatory&#xD;
             medication (including oral or parenteral corticosteroids) within 30 days prior to&#xD;
             enrollment or during the course of the study.&#xD;
&#xD;
          9. Have any uncontrolled current infection;&#xD;
&#xD;
         10. Female subject who is pregnant, lactating planning to become pregnant, or is&#xD;
             breastfeeding;&#xD;
&#xD;
         11. Have any chronic or acute medical condition that, in the opinion of the investigator,&#xD;
             may interfere with the study results or place the subject at undue risk (such as an&#xD;
             immunodeficiency or relevant genetic syndrome);&#xD;
&#xD;
         12. Have any active malignancy or are undergoing treatment for any malignancy other than&#xD;
             non-melanoma skin cancer; Subjects viewed by the Principal Investigator as not being&#xD;
             able to complete the study -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jayashri Krishnan, PhD</last_name>
    <role>Study Director</role>
    <affiliation>JSS Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Philadelphia Institute of Dermatology</name>
      <address>
        <city>Fort Washington</city>
        <state>Pennsylvania</state>
        <zip>19034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parkside Pediatrics</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Pediatrics</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>January 31, 2017</study_first_submitted>
  <study_first_submitted_qc>March 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2017</study_first_posted>
  <last_update_submitted>October 9, 2018</last_update_submitted>
  <last_update_submitted_qc>October 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>viral skin disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Molluscum Contagiosum</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

